UHE-103 / Therapeutics Inc - LARVOL DELTA

Safety, Tolerability, and Pharmacokinetics of UHE-103 Cream in Subjects With Tinea Cruris and/or Tinea Pedis (clinicaltrials.gov) - P1 | N=42 | Completed | Sponsor: Therapeutics, Inc. | Recruiting ➔ Completed | Trial completion date: Nov 2022 ➔ Nov 2023 | Trial primary completion date: Nov 2022 ➔ Nov 2023

Trial completion • Trial completion date • Trial primary completion date • Dermatology

Safety, Tolerability, and Pharmacokinetics of UHE-103 Cream in Subjects With Tinea Cruris and/or Tinea Pedis (clinicaltrials.gov) - P1 | N=40 | Recruiting | Sponsor: Therapeutics, Inc.

New P1 trial • Dermatology